^
    6ms
    Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Fudan University
    New P1 trial • Combination therapy • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    paclitaxel • Tyvyt (sintilimab) • IBI110
    11ms
    Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=6, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=40 --> 6 | Trial completion date: Apr 2023 --> Dec 2023 | Recruiting --> Terminated; Development strategy adjustment
    Enrollment change • Trial completion date • Trial termination • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Tyvyt (sintilimab) • IBI110
    1year
    IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
    New P2 trial • Metastases
    |
    Tyvyt (sintilimab) • IBI110
    over1year
    A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • etoposide IV • IBI110
    over1year
    Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study. (ASCO 2023)
    IBI110 in combination with sintilimab and XELOX demonstrated manageable safety and encouraging efficacy results in patients with first-line gastric adenocarcinoma. This is the first positive trial to show clinical benefits of a LAG3 plus PD-1 inhibitor combined with chemotherapy for this population. Clinical trial information: NCT04085185.
    Clinical • P1 data • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • LAG3 (Lymphocyte Activating 3)
    |
    HER-2 negative
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin • IBI110
    2years
    Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Tyvyt (sintilimab) • IBI110
    over2years
    Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study. (ASCO 2022)
    Background: Sintilimab plus XELOX has been proven to be efficacious in the first line treatment of gastric cancer. In this phase Ib study, IBI110 in combination with sintilimab and chemotherapy was well tolerated in the first line treatment of G/GEJ AC and the clinical benefit need more follow up time to be elucidated.
    Clinical • P1 data • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin • IBI110
    almost3years
    Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Tyvyt (sintilimab) • IBI110
    3years
    Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    Clinical • New P1 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Tyvyt (sintilimab) • IBI110